tetano
Editor, Senior Moderator
Inovio Pharmaceuticals (AMEX:INO) said Tuesday that the first patients have been treated in its clinical study testing immune responses in elderly adults that were immunized with the company's H1N1 universal flu vaccine.
The phase 1 study will look at the ability of Inovio's SynCon vaccine alone, as well as in combination with the 2012 seasonal influenza vaccine, to generate protective levels of immune responses.
The company will also look at the vaccine's ability to generate specific antibody immune responses against unmatched flu strains, and T-cell immune responses that can be helpful in fighting the flu, especially for the elderly, which are absent from current flu vaccines.
Inovio's SynCon technology allows it to design synthetic vaccines with the potential to protect against unmatched sub-types and strains of pathogens, including newly emergent, unknown strains of a virus that will periodically emerge through mutation, as in the case of influenza.
The H3N2, H1N1, and Type B influenza strains represented in each year?s seasonal influenza vaccine are updated annually, but only protect against a single strain within each of these subtypes.
When a selected strain mutates, the annual vaccine may not provide protection, as witnessed with the 2009 swine flu H1N1 pandemic.
..
http://www.proactiveinvestors.com.a...-universal-flu-vaccine-in-elderly--31145.html
The phase 1 study will look at the ability of Inovio's SynCon vaccine alone, as well as in combination with the 2012 seasonal influenza vaccine, to generate protective levels of immune responses.
The company will also look at the vaccine's ability to generate specific antibody immune responses against unmatched flu strains, and T-cell immune responses that can be helpful in fighting the flu, especially for the elderly, which are absent from current flu vaccines.
Inovio's SynCon technology allows it to design synthetic vaccines with the potential to protect against unmatched sub-types and strains of pathogens, including newly emergent, unknown strains of a virus that will periodically emerge through mutation, as in the case of influenza.
The H3N2, H1N1, and Type B influenza strains represented in each year?s seasonal influenza vaccine are updated annually, but only protect against a single strain within each of these subtypes.
When a selected strain mutates, the annual vaccine may not provide protection, as witnessed with the 2009 swine flu H1N1 pandemic.
..
http://www.proactiveinvestors.com.a...-universal-flu-vaccine-in-elderly--31145.html